Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar 9;2(5):259-267.
doi: 10.1200/JGO.2015.002105. eCollection 2016 Oct.

EGFR Mutations in Latinos From the United States and Latin America

Ariel Lopez-Chavez  1 , Anish Thomas  1 , Moses O Evbuomwan  1 , Liqiang Xi  1 , Guinevere Chun  1 , Tatiana Vidaurre  1 , Oscar Arrieta  1 , George Oblitas 3rd  1 , Ana Belen Oton  1 , Alejandro R Calvo  1 , Arun Rajan  1 , Mark Raffeld  1 , Seth M Steinberg  1 , Lorena Arze-Aimaretti  1 , Giuseppe Giaccone  1
Affiliations

EGFR Mutations in Latinos From the United States and Latin America

Ariel Lopez-Chavez et al. J Glob Oncol. .

Abstract

Purpose: Epidermal growth factor receptor (EGFR) mutations confer sensitivity to EGFR tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer (NSCLC). There are limited and conflicting reports on the frequency of EGFR mutations in Latinos.

Patients and methods: Samples from 642 patients with NSCLC from seven institutions in the United States and Latin America were assessed for EGFR mutations (exons 18 to 21) at Clinical Laboratory Improvement Amendments-certified central laboratories.

Results: EGFR mutation analysis was successfully performed in 480 (75%) of 642 patients; 90 (19%) were Latinos, 318 (66%) were non-Latino whites, 35 (7%) were non-Latino Asians, 30 (6%) were non-Latino blacks, and seven (2%) were of other races or ethnicities. EGFR mutations were found in 21 (23%) of 90 Latinos with varying frequencies according to the country of origin; Latinos from Peru (37%), followed by the United States (23%), Mexico (18%), Venezuela (10%), and Bolivia (8%). In never-smoker Latinos and Latinos with adenocarcinoma histology, EGFR mutation frequencies were 38% and 30%, respectively. There was a significant difference in the frequency of EGFR mutations among the different racial and ethnic subgroups analyzed (P < .001), with non-Latino Asians having the highest frequency (57%) followed by Latinos (23%), non-Latino whites (19%), and non-Latino blacks (10%). There was no difference between Latinos (23%) and non-Latinos (22%; P = .78) and Latinos and non-Latino whites (P = .37). Patients from Peru had an overall higher frequency of mutations (37%) than all other Latinos (17%), but this difference only exhibited a trend toward significance (P = .058).

Conclusion: There was no significant difference between the frequency of EGFR mutations in NSCLC in Latinos and non-Latinos.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest and contributions are found at the end of this article.The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Ariel Lopez-ChavezEmployment: Genentech Stock or Other Ownership: GenentechAnish ThomasNo relationship to discloseMoses O. EvbuomwanNo relationship to discloseLiqiang XiNo relationship to discloseGuinevere ChunNo relationship to discloseTatiana VidaurreNo relationship to discloseOscar ArrietaNo relationship to discloseGeorge Oblitas IIINo relationship to discloseAna Belen OtonEmployment: Eli Lilly Honoraria: Pfizer Consulting or Advisory Role: Pfizer Travel, Accommodations, Expenses: Pfizer, Eli LillyAlejandro R. CalvoSpeakers’ Bureau: Genentech, Boehringer IngelheimArun RajanNo relationship to discloseMark RaffeldStock or Other Ownership: Pfizer, GlaxoSmithKlineSeth M. SteinbergNo relationship to discloseLorena Arze-AimarettiNo relationship to discloseGiuseppe GiacconeConsulting or Advisory Role: Astex Pharmaceuticals, Boehringer Ingelheim, Clovis Oncology, Celgene Research Funding: Karyopharm Therapeutics, AstraZeneca

References

    1. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: A SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med. 2002;162:1985–1993. - PubMed
    1. Colby SL, Ortman JM. Projections of the Size and Composition of the U.S. Population: 2014 to 2060—Population Estimates and Projections. https://www.census.gov/content/dam/Census/library/publications/2015/demo....
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957. - PubMed
    1. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742. - PubMed
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246. - PubMed